Research
2017 Research Year-in-Review
Over our past fiscal year—from July 1, 2016, to June 30, 2017—Cure SMA has funded 28 projects with over $2.5 million in new research funding. […]
Read More ›AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101
AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced the U.S. Food and […]
Read More ›Cure SMA-Funded Research Results in 21 Published Journal Articles
An important goal of our research funding strategy is to share scientific findings with the broader scientific community. To help accomplish this goal, scientists who […]
Read More ›Cytokinetics Publishes Clinical Trial Data for CK-2127107
Cytokinetics, Inc. recently announced the publication of results from three early clinical trials in healthy volunteers that evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-2127107. […]
Read More ›Cure SMA-Funded Researcher, Stephen Kolb, Publishes Paper
Cure SMA-funded researcher Stephen Kolb has published a paper in the journal Annals of Neurology, on the results of a study comparing infants affected by […]
Read More ›Biogen Issues Community Update on Spinraza
Biogen has provided the following community statement on Spinraza. Dear Members of the SMA community, As part of our commitment to the SMA community to […]
Read More ›2017 World Muscle Society Congress Recap
From October 3rd through October 7th, Cure SMA attended the 22nd International Annual Congress of the World Muscle Society (WMS) in Saint Malo, France. WMS […]
Read More ›Fall 2017 Issue of Compass Now Available
The fall 2017 issue of Compass is now available online. This issue covers Phase II of the SMA Industry Collaboration, as well as highlights and […]
Read More ›Cure SMA Announces Over $5 Million in New Research and Care Funding
Cure SMA is pleased to announce $5 million in new research funding over the next 12 months. This funding will be used strategically to help […]
Read More ›Genentech/Roche Releases Clinical Trial Update for SUNFISH (RG7916)
Genentech/Roche has provided the below community statement with clinical trial updates for SUNFISH (Type 2/3). The first patient is now enrolled in SUNFISH, as the […]
Read More ›